Patents Assigned to Theratechnologies Inc.
  • Patent number: 9073963
    Abstract: The invention relates to compositions which are useful for inhibiting prostaglandin F2? receptor. The compositions include, but are not limited to, linear peptides, peptide analogs, and peptidomimetics. Methods of using the compositions of the invention to treat preterm labor and dysmenorrhea are disclosed.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: July 7, 2015
    Assignees: Universite De Montreal, Theratechnologies, Inc.
    Inventors: Krishna Peri, Felix Polyak, William Lubell, Eryk Thouin, Sylvain Chemtob
  • Patent number: 8871713
    Abstract: Stabilized solid and liquid pharmaceutical formulations comprising a GRF molecule as active ingredient, such as GRF analogs including those comprising an N-terminal-attached hydrophobic moiety, such as [trans-3-hexenoyl]hGHRH (1-44) amide, are disclosed. The formulation comprises a GRF molecule or a pharmaceutically acceptable salt thereof and a ?-cyclodextrin which is not conjugated to the GRF molecule or salt thereof. Also disclosed is the use of the formulation for the treatment of various conditions, methods of preparing the formulation, as well as kits containing it. Methods of stabilizing (e.g., with respect to chemical stability) such GRF molecules, as well as methods of inhibiting their deamidation at Asn8, are also disclosed.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 28, 2014
    Assignee: Theratechnologies Inc.
    Inventors: Kirill I Shingel, Daniel Fleury
  • Patent number: 8822413
    Abstract: A bifunctional hormone exhibiting an alpha-MSH activity and a natriuretic peptide activity is described. The bifunctional hormone comprises for example a first domain having alpha-MSH related hormonal activity covalently linked to a second domain having natriuretic peptide related hormonal activity. The bifunctional hormone of the present invention is useful for example for the prevention and/or treatment of renal related diseases or conditions, such as acute renal failure (ARF) or acute kidney injury (AKI).
    Type: Grant
    Filed: July 7, 2008
    Date of Patent: September 2, 2014
    Assignee: Theratechnologies Inc.
    Inventors: Krishna G. Peri, Abdelkrim Habi
  • Patent number: 8481489
    Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: July 9, 2013
    Assignee: Theratechnologies Inc.
    Inventors: Thierry Abribat, Andre De Villers, Alcide Chapdelaine, Soraya Allas, Denis Gravel
  • Patent number: 8435945
    Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: May 7, 2013
    Assignee: Theratechnologies Inc.
    Inventors: Thierry Abribat, Andre De Villers, Alcide Chapdelaine, Soraya Allas, Denis Gravel
  • Patent number: 8361964
    Abstract: Novel GRF analogs having GRF activity are described herein, as well as uses thereof for example as a GRF receptor agonist, e.g., to induce growth hormone secretion in a subject or biological system.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: January 29, 2013
    Assignee: Theratechnologies Inc.
    Inventors: Krishna G. Peri, Abdelkrim Habi
  • Patent number: 8314066
    Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
    Type: Grant
    Filed: October 23, 2007
    Date of Patent: November 20, 2012
    Assignee: Theratechnologies Inc.
    Inventors: Thierry Abribat, Andre De Villers, Alcide Chapdelaine, Soraya Allas, Denis Gravel
  • Publication number: 20110105390
    Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for increasing muscle function in a subject. Also disclosed herein are corresponding methods, packages and compositions.
    Type: Application
    Filed: January 11, 2011
    Publication date: May 5, 2011
    Applicant: Theratechnologies Inc.
    Inventors: Bruno LUSSIER, Luc Vachon, Soraya Allas, Thierry Abribat
  • Publication number: 20100087366
    Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
    Type: Application
    Filed: September 26, 2008
    Publication date: April 8, 2010
    Applicant: Theratechnologies Inc.
    Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
  • Patent number: 7538185
    Abstract: Novel GLP-1 analogs having improved biological potency as well as extended pharmacological activity are described herein. More specifically, the present invention relates to GLP-1 analogs (28 or 29 aa long) comprising amino acid substitutions at one or more of the following positions: 8, 20, 27, 30 and 33.
    Type: Grant
    Filed: January 7, 2005
    Date of Patent: May 26, 2009
    Assignee: Theratechnologies Inc.
    Inventors: Krishna Peri, Daniel Abran, Abdelkrim Habi
  • Patent number: 7521530
    Abstract: The invention relates to compositions which are useful for inhibiting prostaglandin F2?receptor. The compositions include, but are not limited to, linear peptides, peptide analogs, and peptidomimetics. Methods of using the compositions of the invention to treat preterm labor and dysmenorrhea are disclosed.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: April 21, 2009
    Assignees: Universite De Montreal, Theratechnologies, Inc.
    Inventors: Krishna Peri, Felix Polyak, William Lubell, Eryk Thouin, Sylvain Chemtob
  • Publication number: 20090088383
    Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
    Type: Application
    Filed: September 26, 2008
    Publication date: April 2, 2009
    Applicant: Theratechnologies Inc.
    Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdlaine
  • Publication number: 20090011997
    Abstract: A bifunctional hormone exhibiting an alpha-MSH activity and a natriuretic peptide activity is described. The bifunctional hormone comprises for example a first domain having alpha-MSH related hormonal activity covalently linked to a second domain having natriuretic peptide related hormonal activity. The bifunctional hormone of the present invention is useful for example for the prevention and/or treatment of renal related diseases or conditions, such as acute renal failure (ARF) or acute kidney injury (AKI).
    Type: Application
    Filed: July 7, 2008
    Publication date: January 8, 2009
    Applicant: Theratechnologies Inc.
    Inventors: Krishna G. Peri, Abdelkrim Habi
  • Publication number: 20090011985
    Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
    Type: Application
    Filed: October 23, 2007
    Publication date: January 8, 2009
    Applicant: Theratechnologies Inc.
    Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
  • Patent number: 7414029
    Abstract: Antagonistic peptides of prostaglandin E2 receptor subtype EP4 and their use in the treatment or prevention of medical conditions associated with oligouric nephropathy, bone resorption, abnormal intestinal crypt cell proliferation or patency of the ductus arteriosus and the like are provided herein. The antagonistic peptides of the present invention can include the following formula: X-A-RnYm wherein “X” is a hydrogen atom or an amine protecting group producing a carbamate or an amide when reacting with the amine; “A” is L-(4,4?)-biphenylalanine or D-(4,4?)-biphenylalanine; “R” is an amino acid selected from the group consisting of threonine, serine, tyrosine, glutamic acid, alanine, leucine and glycine; “Y” is lysine; “n” is an integer ranging from 5 to 7; and “m” is an integer ranging from 0 to 2.
    Type: Grant
    Filed: October 19, 2004
    Date of Patent: August 19, 2008
    Assignee: Theratechnologies, Inc.
    Inventors: Krishna G. Peri, Serge Moffett, Daniel Abran, Annie Bergeron
  • Patent number: 7316997
    Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
    Type: Grant
    Filed: October 20, 2004
    Date of Patent: January 8, 2008
    Assignee: Theratechnologies Inc.
    Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
  • Publication number: 20060292613
    Abstract: A GPCR-like protein is described, as well as inhibitory/antagonistic compounds and compositions comprising such inhibitors/antagonists of the protein. Such compounds may be used for treating elevated intraocular pressure and conditions associated with elevated intraocular pressure, such as glaucoma.
    Type: Application
    Filed: July 12, 2006
    Publication date: December 28, 2006
    Applicant: Theratechnologies Inc.
    Inventors: Krishna Peri, Serge Moffett, Daniel Abran
  • Patent number: 7094761
    Abstract: A GPCR-like protein is described, as well as inhibitory/antagonistic compounds and compositions comprising such inhibitors/antagonists of the protein. Such compounds may be used for treating elevated intraocular pressure and conditions associated with elevated intraocular pressure, such as glaucoma.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: August 22, 2006
    Assignee: Theratechnologies Inc.
    Inventors: Krishna G. Peri, Serge Moffett, Daniel Abran
  • Patent number: 7067488
    Abstract: The present invention relates to a GLP-1 peptide having the following formula, or a pharmaceutically acceptable salt thereof: X-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-lle-Ala-Trp-Leu-val-Lys-Gly-Arg-Y (SEQ ID NO. 1) wherein X is a rigidifying hydrophobic moiety and wherein Y is selected from the group consisting of OH, NH2 and Gly-OH. Moreover, the present invention relates to pharmaceutical compositions comprising a therapeutically effective amount of a peptide of the present invention, or a pharmaceutically acceptable salt thereof, in association with at least one constituent selected from a pharmaceutically acceptable carrier, diluent, and excipient.
    Type: Grant
    Filed: September 25, 2003
    Date of Patent: June 27, 2006
    Assignee: TheraTechnologies Inc.
    Inventors: Denis Gravel, Krishna Peri, Thierry Abribat, Abdelkrim Habi
  • Publication number: 20050197288
    Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
    Type: Application
    Filed: October 20, 2004
    Publication date: September 8, 2005
    Applicant: Theratechnologies Inc.
    Inventors: Thierry Abribat, Andre Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine